Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

U.S. approval of Eli Lilly's obesity pill is expected to expand the GLP‑1 category, according to Novo Nordisk EVP Jamey Millar. Novo is rolling out a new subscription model to respond to category growth and intensified competition. The approval likely broadens the market opportunity for GLP‑1 therapies while increasing competitive pressure on pricing, access and commercial strategies.

Analysis

U.S. approval of Eli Lilly's obesity pill is expected to expand the GLP‑1 category, according to Novo Nordisk EVP Jamey Millar. Novo is rolling out a new subscription model to respond to category growth and intensified competition. The approval likely broadens the market opportunity for GLP‑1 therapies while increasing competitive pressure on pricing, access and commercial strategies.